Medical Crossfire®: Optimal Lipid Management for Primary Care Practitioners: An Update on PCSK9 Inhibitors

 


Release Date: August 1, 2018
Expiration Date: August 1, 2019
Media: Internet - based

Activity Overview

“Optimal Lipid Management for Primary Care Practitioners: An Update on PCSK9 Inhibitors: A Medical Crossfire® Activity” is designed to update primary care providers and other health care professionals on the evolving landscape of lipid-lowering therapy. During this Medical Crossfire®, expert faculty, including a lipidologist, cardiologist, primary care physician, and allied health care professional, will engage in a multidisciplinary roundtable discussion to discuss how to best optimize and individualize hypercholesterolemia management with newer therapies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This CME activity is primarily intended for community clinicians, primary care clinicians, and cardiologists, as well as other professionals who treat patients with hyperlipidemia.  These HCPs are in positions to educate patients and guide treatment decisions.

Learning Objectives

Upon completion of this CME activity, you should be better prepared to:

  1. Describe the latest guidelines and recommendations on cholesterol management from major clinical organizations.

  2. Discuss potential cholesterol-lowering therapies beyond statins and explain when these nonstatin therapies should be considered.

  3. Summarize in detail the indications for proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i) therapy.
     

Faculty Presenters

Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
University of Florida
Gainesville, Florida

Disclosure: has no financial information to disclose.

Seth S. Martin, MD, MHS 
Director, Lipid Clinic
Division of Cardiology
Department of Medicine
Johns Hopkins Hospital
Baltimore, Maryland

Disclosure: Consultant: Scientific advisory boards for Amgen and Sanofi/Regeneron

Spouse employment role: Pharmacist at Walgreens

Alan Brown, MD, FACC, FAHA, FNLA, FASPC
Director, Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, Illinois
Co-Director, Cardiology Service Line
Advocate Medical Group
Park Ridge, Illinois
Clinical Associate Professor
Loyola Stritch School of Medicine
Maywood, Illinois

Disclosure: Consultant: Amarin, Amgen, Kastle, Kowa, Pfizer, Regeneron; Speaker’s Bureau: Amgen Regeneron, Sanofi

Kathleen H. Byrne, MSN, CRNP, FPCNA
Cardiovascular Nurse Practitioner
Johns Hopkins University
Advanced Lipid Disorders Clinic
Pediatric Cardiology
Baltimore, Maryland 

Disclosure: has no financial information to disclose.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
 

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and is a provider approved by the California Board of Registered Nursing (CBRN).
 
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
All other health care professionals completing this course will be issued a statement of participation.

Off-Label Disclosure/Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.







Become a Member

Forgot Password?
Filter By